Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen G Chadwick

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
AIDS (London, England)|March 22, 2017
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infectionCarolyn Bolton Moore, Edmund V Capparelli, Pearl Samson, et al.
AIDS and Behavior|March 24, 2026
Low SARS-CoV-2 Positivity in a Large, Diverse US-Based Study of Persons Affected by HIVSuzanne Siminski, Brad Karalius, Yanling Huo, et al.
The New England Journal of Medicine|September 2, 2022
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United StatesKunjal Patel, Yanling Huo, Jennifer Jao, et al.
Frontiers in Pediatrics|June 15, 2018
Surviving and Thriving-Shifting the Public Health Response to HIV-Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child WorkshopAmy L Slogrove, Renaud Becquet, Ellen G Chadwick, et al.
The Lancet. HIV|November 26, 2020
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept studyTheodore D Ruel, Edmund V Capparelli, Camlin Tierney, et al.
AIDS (London, England)|November 30, 2020
Pharmacokinetics and safety of maraviroc in neonatesJulia C Rosebush, Brookie M Best, Ellen G Chadwick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2022
Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of LifeBryan S Nelson, Camlin Tierney, Deborah Persaud, et al.
AIDS (London, England)|March 23, 2021
In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newbornsShu-Hong Lin, Youjin Wang, Stephen W Hartley, et al.
The Journal of Infectious Diseases|June 22, 2022
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative ChildrenColeen K Cunningham, Ruth A Karron, Petronella Muresan, et al.
The Lancet. HIV|December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept studyDeborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|March 22, 2017
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infectionCarolyn Bolton Moore, Edmund V Capparelli, Pearl Samson, et al.
AIDS and Behavior|March 24, 2026
Low SARS-CoV-2 Positivity in a Large, Diverse US-Based Study of Persons Affected by HIVSuzanne Siminski, Brad Karalius, Yanling Huo, et al.
The New England Journal of Medicine|September 2, 2022
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United StatesKunjal Patel, Yanling Huo, Jennifer Jao, et al.
Frontiers in Pediatrics|June 15, 2018
Surviving and Thriving-Shifting the Public Health Response to HIV-Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child WorkshopAmy L Slogrove, Renaud Becquet, Ellen G Chadwick, et al.
The Lancet. HIV|November 26, 2020
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept studyTheodore D Ruel, Edmund V Capparelli, Camlin Tierney, et al.
AIDS (London, England)|November 30, 2020
Pharmacokinetics and safety of maraviroc in neonatesJulia C Rosebush, Brookie M Best, Ellen G Chadwick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2022
Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of LifeBryan S Nelson, Camlin Tierney, Deborah Persaud, et al.
AIDS (London, England)|March 23, 2021
In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newbornsShu-Hong Lin, Youjin Wang, Stephen W Hartley, et al.
The Journal of Infectious Diseases|June 22, 2022
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative ChildrenColeen K Cunningham, Ruth A Karron, Petronella Muresan, et al.
The Lancet. HIV|December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept studyDeborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
Pageof 6